159 related articles for article (PubMed ID: 31874475)
21. Endometrial damage by antiestrogens in a postmenopausal breast cancer patient.
Ceci O; Bettocchi S; Marello F; Pellegrino A; Impedovo L; Di Venere R
Acta Obstet Gynecol Scand; 2002 Feb; 81(2):174-5. PubMed ID: 11942911
[No Abstract] [Full Text] [Related]
22. Time-dependent effect of tamoxifen therapy on endometrial pathology in asymptomatic postmenopausal breast cancer patients.
Cohen I; Altaras MM; Shapira J; Tepper R; Rosen DJ; Cordoba M; Zalel Y; Figer A; Yigael D; Beyth Y
Int J Gynecol Pathol; 1996 Apr; 15(2):152-7. PubMed ID: 8786205
[TBL] [Abstract][Full Text] [Related]
23. [Tamoxifen and endometrial pathology].
Negoiţă M; Terinte C; Mihailovici MS
Rev Med Chir Soc Med Nat Iasi; 2010; 114(4):1114-7. PubMed ID: 21500468
[TBL] [Abstract][Full Text] [Related]
24. The endometrial effects of SERMs.
Cano A; Hermenegildo C
Hum Reprod Update; 2000; 6(3):244-54. PubMed ID: 10874569
[TBL] [Abstract][Full Text] [Related]
25. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.
Pinkerton JV; Goldstein SR
Menopause; 2010; 17(3):642-53. PubMed ID: 20107426
[TBL] [Abstract][Full Text] [Related]
26. Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis.
Pinkerton JV; Archer DF; Utian WH; Menegoci JC; Levine AB; Chines AA; Constantine GD
Menopause; 2009; 16(6):1102-8. PubMed ID: 19546825
[TBL] [Abstract][Full Text] [Related]
27. Endometrial tubal metaplasia in a young puerperal woman after breast cancer.
Di Benedetto L; Giovanale V; Caserta D
Int J Clin Exp Pathol; 2015; 8(6):7610-3. PubMed ID: 26261678
[TBL] [Abstract][Full Text] [Related]
28. Indication of hysteroscopy in tamoxifen treated breast cancer patients.
Taponeco F; Curcio C; Fasciani A; Giuntini A; Artini PG; Fornaciari G; Petraglia F; Genazzani AR
J Exp Clin Cancer Res; 2002 Mar; 21(1):37-43. PubMed ID: 12071527
[TBL] [Abstract][Full Text] [Related]
29. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients.
Cheng WF; Lin HH; Torng PL; Huang SC
Gynecol Oncol; 1997 Aug; 66(2):233-7. PubMed ID: 9264568
[TBL] [Abstract][Full Text] [Related]
30. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
31. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
Tuxen MK; Nielsen DL; Lindberg H; Kamby C
Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
[TBL] [Abstract][Full Text] [Related]
32. Value of endometrial thickness in diagnosis of endometrial hyperplasia during selective estrogen receptor modulator therapy in premenopausal breast cancer patients.
Zhang G; Yu X; Sun Z; Zhu L; Lang J
J Gynecol Obstet Hum Reprod; 2021 Oct; 50(8):101929. PubMed ID: 33022449
[TBL] [Abstract][Full Text] [Related]
33. Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a prospective gynecological ultrasound substudy.
Kieback DG; Harbeck N; Bauer W; Hadji P; Weyer G; Menschik T; Hasenburg A
Gynecol Oncol; 2010 Dec; 119(3):500-5. PubMed ID: 20832103
[TBL] [Abstract][Full Text] [Related]
34. Indication for histological examination of endometrium in breast carcinoma patients receiving tamoxifen therapy.
Ito T; Katagiri C; Murata Y; Hamazoe R; Morita K
J Obstet Gynaecol Res; 2001 Jun; 27(3):141-5. PubMed ID: 11561830
[TBL] [Abstract][Full Text] [Related]
35. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women.
Archer DF; Pinkerton JV; Utian WH; Menegoci JC; de Villiers TJ; Yuen CK; Levine AB; Chines AA; Constantine GD
Menopause; 2009; 16(6):1109-15. PubMed ID: 19543129
[TBL] [Abstract][Full Text] [Related]
36. Postmenopausal tamoxifen treatment and endometrial pathology.
Cohen I; Altaras MM; Shapira J; Tepper R; Beyth Y
Obstet Gynecol Surv; 1994 Dec; 49(12):823-9. PubMed ID: 7885659
[TBL] [Abstract][Full Text] [Related]
37. Tamoxifen and endometrial cancer. Is screening necessary? A review of the literature.
Machado F; Rodríguez JR; León JP; Rodríguez JR; Parrilla JJ; Abad L
Eur J Gynaecol Oncol; 2005; 26(3):257-65. PubMed ID: 15991522
[TBL] [Abstract][Full Text] [Related]
38. The endometrium in asymptomatic breast cancer patients on tamoxifen: value of transvaginal ultrasonography with saline infusion and Doppler flow.
Develioğlu OH; Omak M; Bilgin T; Esmer A; Tüfekçi M
Gynecol Oncol; 2004 May; 93(2):328-35. PubMed ID: 15099941
[TBL] [Abstract][Full Text] [Related]
39. Postmenopausal endometrial pathologies with tamoxifen treatment: comparison between hysteroscopic and hysterectomy findings.
Cohen I; Azaria R; Aviram R; Bernheim J; Tepper R; Cordoba M; Beyth Y
Gynecol Obstet Invest; 1999; 48(3):187-92. PubMed ID: 10545744
[TBL] [Abstract][Full Text] [Related]
40. [Usefulness of ultrasound endometrium thickness measurement in diagnosis of endometrium pathology in women with abnormal peri- and postmenopausal bleeding].
Pieta W; Radowicki S
Ginekol Pol; 2009 Jul; 80(7):503-7. PubMed ID: 19697813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
